We and others have recently reported highly efficient liver gene transfer with adeno-associated virus 8 (AAV-8) pseudotypes, i.e., AAV-2 genomes packaged into AAV-8 capsids. Here we studied whether liver transduction could be further enhanced by using viral DNA packaging sequences (inverted terminal repeats [ITRs]) derived from AAV genotypes other than 2. To this end, we generated two sets of vector constructs carrying expression cassettes embedding a gfp gene or the human factor IX (hfIX) gene flanked by ITRs from AAV genotypes 1 through 6. Initial in vitro analyses of gfp vector DNA replication, encapsidation, and cell transduction revealed a surprisingly high degree of interchangeability among the six genotypes. For subsequent in vivo studies, we cross-packaged the six hfIX variants into AAV-8 and infused mice via the portal vein with doses of 5 ؋ 10 10 to 1.8 ؋ 10 12 particles. Notably, all vectors expressed comparably high plasma hFIX levels within a dose cohort over the following 6 months, concurrent with the finding of equivalent vector DNA copy numbers per cell. Partial hepatectomies resulted in ϳ80% drops of hFIX levels and vector DNA copy numbers in all groups, indicating genotype-independent persistence of predominantly episomal vector DNA. Southern blot analyses of total liver DNA in fact confirmed the presence of identical and mostly nonintegrated molecular vector forms for all genotypes. We conclude that, unlike serotypes, AAV genotypes are not critical for efficient hepatocyte transduction and can be freely substituted. This corroborates our current model for AAV vector persistence in the liver and provides useful information for the future design and application of recombinant AAV.Gene transfer vectors based on the single-stranded DNA parvovirus AAV (adeno-associated virus) are enormously popular and powerful tools for in vivo delivery of small DNA expression cassettes. The list of human genes carried by such cassettes is growing steadily and spans a wealth of clinically relevant candidates expressing blood coagulation factors (28), the cystic fibrosis transmembrane conductance regulator (18), or dystrophin (32), among many others. Most recently, AAV vectors have begun to attract particular attention for delivery of short hairpin RNAs, and indeed, with a packaging capacity of 5 kb DNA and the promise to mediate safe and persistent gene transfer, they appear as bona fide tools for in vivo RNA interference applications (27).A major reason for AAV's broad and growing appeal is the feasibility to pseudotype the recombinant viral DNA, i.e., to generate particles in which the vector DNA (genotype) and the viral capsid (serotype) differ in their AAV origins (23). The resulting hybrid particles are typically characterized by unique receptor tropisms and are distinctly recognized by the host immune system, as determined by the capsid. Thus, the pseudotyping approach has dramatically extended the array of cells and tissues susceptible to AAV gene transfer and relieved some of the concerns associated with t...